NCT04468984 | M20-178 | DRUG CO
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
NCT02775383 | NHLBI-MDS | ECOG-A
The National Myelodysplastic Syndromes (MDS) Study
NCT05210790 | PTG-300-11 | DRUG CO
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
